Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afatinib + panitumumab
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Afatinib + panitumumab is a combination therapy that targets the epidermal growth factor receptor (EGFR) through dual inhibition mechanisms. Afatinib is an ErbB family blocker that irreversibly inhibits signaling from EGFR (ErbB1), HER2 (ErbB2), HER4 (ErbB4), and all relevant ErbB family dimers. Panitumumab is a fully human IgG2 monoclonal antibody that binds specifically to the extracellular domain of EGFR, preventing binding of endogenous ligands such as epidermal growth factor (EGF) or transforming growth factor-alpha. This combination has been studied for overcoming resistance in EGFR-mutated non-small-cell lung cancer.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on afatinib + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afatinib + panitumumab.